Head to Head Review: Pluri (NASDAQ:PLUR) and Oramed Pharmaceuticals (NASDAQ:ORMP)

Pluri (NASDAQ:PLUR) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk and earnings.

Risk and Volatility

Pluri has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Institutional and Insider Ownership

16.6% of Pluri shares are owned by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 20.8% of Oramed Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pluri and Oramed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pluri	-2,162.08%	N/A	-106.59%
Oramed Pharmaceuticals	N/A	-5.17%	-4.54%

Analyst Recommendations

This is a summary of recent recommendations for Pluri and Oramed Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1	0	0	0	1.00
Oramed Pharmaceuticals	0	1	0	0	2.00

Valuation and Earnings

This table compares Pluri and Oramed Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.34 million	11.32	-$22.58 million	($4.53)	-0.30
Oramed Pharmaceuticals	$2.00 million	104.21	$64.05 million	$4.12	1.22

Oramed Pharmaceuticals has higher revenue and earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Oramed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Oramed Pharmaceuticals beats Pluri on 9 of the 12 factors compared between the two stocks.

About Pluri

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.